Market Trends of India In-Vitro Diagnostics Industry
This section covers the major market trends shaping the India In-Vitro Diagnostics Market according to our research experts:
Molecular Diagnostics Segment is Expected to Grow in the India In-Vitro Diagnostics Market Over the Forecast Period
The molecular diagnostics segment is expected to witness significant growth in the in-vitro diagnostics market over the forecast period owing to the factors such as large outbreaks of bacterial and viral epidemics in India, increasing demand for point-of-care diagnostics, and rapidly evolving technology.
Molecular diagnostic devices are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. Based on the technology, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging.
In addition, the outbreak of COVID-19 in the country increased the demand for molecular diagnostics, boosting the market's growth. For instance, in May 2022, Cipla announced the commercialization of its real-time COVID-19 RT-PCR test kit in India. In addition, in July 2021, Abbott launched a COVID-19 home test kit in India to detect the SARS-CoV-2 virus in adults and children with or without symptoms for INR 325 per pack. The company delivers millions of Panbio COVID-19 rapid antigen tests, available for self-use, to ease the burden on healthcare systems in urban and rural India.
Furthermore, the rising advancements in molecular diagnostics and new product launches in India are projected to boost segment growth over the forecast period. For instance, in September 2022, BD Diagnostics, India, launched BD MAX molecular diagnostic system and BD MAX MDR-TB panel in India that is used to test and simultaneously detected Tb-causing bacteria and determine if the bacteria contain mutations associated with resistance to two important first-line drugs such as isoniazid (INH) and rifampicin (RIF) respectively. Similarly, in November 2021, Genes2Me, one of the leading in-vitro diagnostics manufacturers, recently launched its new product RT- Direct Multiplex RTPCR kit, a first-of-its-kind 'Made in India' product, for COVID-19. This kit is based on the RT-PCR method with coverage of 3 target genes specific to SARS-COV-2.
Therefore, owing to the abovementioned factors such as the growing technological advancements and rising product launches, the studied segment is anticipated to grow over the forecast period.
Infectious Disease Segment is Expected to Have the Significant Market Share in the India In-Vitro Diagnostics Market Over the Forecast Period
The infectious disease segment is expected to witness healthy growth in the in-vitro diagnostic market in India over the forecast period. The factors attributing to the market growth are the rising prevalence of infectious diseases, the shift in emphasis from centralized laboratories to point-of-care testing, and rising research and development activities on infectious disease diagnostics.
Point-of-care diagnostics offer quick, helpful information for patient care right where the disease is being experienced. As a result, several significant firms are concentrating on research and development initiatives to create point-of-care and in-vitro diagnostic solutions. This is anticipated to increase the market growth over the forecast period. For instance, in September 2022, J Mitra launched its fourth Generation Elisa-based HCV Test, the HCV Gen 4 Ag, and Ab Microlisa, an in-vitro qualitative enzyme-linked immunosorbent assay for detecting HCV core antigen and antibodies against HCV (anti-HCVs) in human serum or plasma.
Additionally, in August 2022, Molbio Diagnostics and Truenat technology launched a new test for differential diagnosis of HIV 1 and HIV 2, the Truenat RT-PCR Test, with viral loads within 60 minutes. The Truenat is a point-of-care portable, battery-operated, IoT-enabled platform that can test over 35 diseases, including COVID-19, TB, Hepatitis, HIV, HPV, Dengue, Malaria, etc. Similarly, in August 2022, BD Diagnostic launched a rapid molecular tool, BD MAX molecular diagnostic system and BD MAX MDR-TB panel in India, that helps clinicians rapidly test for TB and multi-drug resistance as a first-line test. Thus, such launches in the country are expected to increase the growth of the studied segment, which is anticipated to augment the market growth over the forecast period.
Furthermore, the rising awareness among the population regarding the spread of infectious diseases and the need for a diagnostic test is also expected to increase the demand for in-vitro diagnostic products in the country, hence boosting segment growth. For instance, in September 2022, Fujifilm India Pvt Ltd launched the second phase of its campaign on tuberculosis, 'Never Stop Screening to Reduce Diagnostic Delays,' to increase awareness of TB as a curable disease and promote screening and early diagnosis among the rural and urban population in India.
Therefore, owing to factors such as the rising company activities in developing products, increasing product launches, and growing awareness for diagnostic tests and infectious diseases among the population, the studied segment is expected to grow over the forecast period.
